Quantitative indices of F-18 FDG PET/CT in assessing cardiovascular and non-cardiovascular manifestations of IgG4-related disease and treatment response

Abstract

Background IgG4-related disease (IgG4-RD) is a heterogenous autoimmune disorder characterised by inflammatory lesions. Diagnostic imaging, such as FDG PET/CT, is critical in evaluation of the disease, especially for potentially lethal cardiovascular manifestations. This retrospective study examines the usefulness of semi-quantitative parameters of FDG PET/CT in monitoring IgG4-RD in patients with and without cardiovascular manifestations. Methods Patients diagnosed with IgG4-RD who underwent a FDG PET/CT scan were identified and classified based on presence or absence of cardiovascular disease. Clinical and laboratory data were extracted and compared to three FDG PET/CT semiquantitative parameters: standardised uptake value (SUV), metabolic tumour volume (MTV), and total lesion glycolysis (TLG). These data were also compared in patients before and after receiving immunosuppressive therapy. Results Forty-six patients identified were divided into an eight member subgroup of patients with cardiovascular manifestations, and a thirty-eight member subgroup of patients without. Patients with cardiovascular lesions were most frequently identified incidentally on imaging evaluation for other diseases (37.5%), with none presenting with chest pain or other cardiovascular symptoms. Ten patients with pre-treatment and post-treatment FDG PET/CT scans demonstrated significant decreases in all semiquantitative parameters, with no significant decrease in total IgG or ESR. The decrease in SUVmax, MTV, and TLG following therapy was replicated in patients with and without cardiovascular manifestations. Conclusion FDG PET/CT is an important investigation to determine all sites of involvement in this multisystemic disease, and to rule out life-threatening cardiovascular manifestations even in the absence of symptoms. Semi-quantitative parameters such as SUVmax, MTV, and TLG are useful in assessing treatment response in patients with or without cardiovascular manifestations. There are no serological substitutes that can quantify the extent of disease involvement like FDG PET/CT.

Current progress and future perspectives in total‐body PET imaging, part I: Data processing and analysis

“…Novel tumor burden measures modified from traditional metabolic tumor volume and total lesion glycolysis can be devised for 18 F‐FDG [129] and PSMA [130, 131]. For non‐oncological systemic disease, a similar concept can be applied to evaluate the usefulness of semi‐quantitative volumetric parameters for monitoring glucose consumption in IgG4‐related diseases [132], COVID‐19 [133], and atherosclerosis [134]. While it remains unclear how the spatial texture features of TB‐PET compare with the ones from conventional scanners [135], TB‐PET does allow assessment of tracer uptake change with a high temporal resolution, which opens the opportunity to compute radiomics along the temporal domain.…”